Revenues below expectation: Dishman Pharmaceuticals & Chemicals’ (DPCL’s) revenue reduced by 15.2% (YoY) - from Rs2.93bn to Rs2.48bn (we expected Rs2.57bn). Segment-wise, revenue from CRAMS reduced by 24.1% - from Rs2.22bn to Rs1.72bn. This reduction in revenue is because of lower business from Carbogen Amcis (CA). Revenue from marketable molecule (MM) segment increased by 16.5% - from Rs649m to Rs756m. In the MM category, revenues from Quats segment grew marginally by 7.4% - from Rs369m to Rs396m. Revenues from the business of Vitamin D, acquired from Solvay grew by 28.5% YoY from Rs280m to Rs360m...

To read full research report you can refer to:
http://www.dsij.in/productattachment...man%20phar.pdf

Source: Dalal Street Investment Journal
Dalal Street Investment Journal